{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '9.', 'STUDY DRUG MATERIALS AND MANAGEMENT', '9.1.', 'Study Drug', 'Specific details regarding study drug supplies, dose preparation, and accountability will be', 'provided in the Investigational Product Manual supplied to the sites.', '9.1.1.', 'Identity of Study Drug', '9.1.1.1.', 'Chemical Name and Structural Formulas', 'Generic name:', 'Olopatadine hydrochloride', 'Chemical name:', '(Z)-11-[3-(dimethylamino)propylidene]-6,11-', 'dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride', 'Structural formula:', 'N', 'CO2H', '. HCI', '9.1.1.2.', 'Mometasone Furoate', 'Generic name:', 'Mometasone furoate', 'Chemical name:', '9,21-Dichloro-11\u00df,17-dihydroxy-16a-methylpregna-1,4-diene-', '3,20-dione17-(2 furoate) monohydrate', 'Structural formula:', 'CIH2C', 'O', 'O', '11', 'HO', 'o', 'CH3', 'o', 'CI', 'o', '.H2O', '9.1.2.', 'Placebo', 'Placebo will be prepared using the same vehicle as the active products. The placebo NS bottle', 'will be identical to that of active treatments. The placebo NS will be packaged in primary and', 'secondary packaging similar to that of the active treatments to maintain study drug blinding.', 'Glenmark', 'CONFIDENTIAL', 'Page 42 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '9.2.', 'Study Drug Packaging and Labeling', 'Each of the IPs will be packed as per Good Manufacturing Practice guidelines. The IP kits will', 'be packed as per the visit schedule to cover the treatment duration. The individual subject kit', 'will at a minimum be labeled as per FDA guidance (CFR Title 21, 2017).', 'The Study Monitor should be notified immediately of the details of any supplies that are', 'inadvertently damaged or unaccountable for any reason. These will be documented on drug', 'accountability logs that will be collected by the Study Monitor at the end of the study or on', 'request by the Sponsor.', '9.3.', 'Study Drug Storage', 'The IP should be stored upright, at controlled room temperature 15\u00b0 to 25\u00b0 Celsius', '(59\u00b0 to 77\u00b0 Fahrenheit), not frozen or refrigerated, and protected from light. Subjects will be', 'informed about the storage conditions for the IP.', '9.4.', 'Study Drug Preparation', '9.5.', 'Administration', 'Each study medication bottle will containt', 'metered sprays. The study medication will be', 'dispensed to the subjects (parents/caregivers/legal guardians, as applicable) at the study site after', 'adequate training using a placebo NS bottle.', 'The subjects (with the assistance from parents/caregivers/legal guardians, as needed) will be', 'asked to take their daily double-blind, study medication for a period of 14 days (2 weeks)', 'following a 7 to 10 day, single-blind, placebo run-in period. The first dose (AM dose on Day 1)', 'will be administered in the clinic at the Randomization Visit (Visit 2). The AM dose of the day', 'of the Treatment Visit (Visit : 3) will also be administered at the clinic. All other doses will be', 'self-administered at home (with assistance from parents/guardians/caregivers,as needed). The', 'last scheduled dose will be the PM dose on the day before the Final Visit/Discontinuation Visit', '(Visit 4). Study drug should not be taken (either at home or at the clinic) on the morning of the', 'Final Visit/Discontinuation Visit (Visit 4).', 'Subjects will self-administer the study medication during specified study visits under the', 'supervision of the study personnel (with assistance from parents/guardians/caregivers, as', 'needed). Additionally, subjects will self-administer the study medication at home BID per the', 'subject instructions provided during the single blind placebo run-in period and the treatment', 'period (with assistance from parents/guardians/caregivers, as needed). Subjects (parents/legal', 'guardians/caregivers, as needed) will be adequately trained in the proper use of the study', 'medication NS bottle at the specified visits as well as reviewing the subject study medication', 'instructions.', 'Detailed instructions for the proper use of the treatment NS bottles are provided in Appendix 1.', '9.6.', 'Study Drug Accountability', 'The Investigator (or designee) is responsible for study drug accountability and its documentation', 'at the site. The Investigator must also ensure that the dispensing and recording of study drug is', 'Glenmark', 'CONFIDENTIAL', 'Page 43 of 90']\n\n###\n\n", "completion": "END"}